You have 9 free searches left this month | to do more

pembrolizumab

Pembrolizumab is a drug used to treat Melanoma, Non-small Cell Lung Cancer, Breast Cancer, and other conditions. Pembrolizumab is being actively studied in 850 studies and prior, has been studied in 133.

Top SponsorsTop SitesTop Investigators
Merck Sharp & Dohme Corp.Memorial Sloan Kettering Cancer CenterCCTU
M.D. Anderson Cancer CenterDana Farber Cancer InstituteDavid Reardon, MD
Memorial Sloan Kettering Cancer CenterMassachusetts General HospitalJeeyun Lee
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
S
Recruiting
  • Gastric Cancer
  • Pembrolizumab
  • Seoul, Korea, Republic of
    Samsung Medical Center
2021-12-23
Dec 23, 2021
M
Active, not recruiting
  • Thyroid
  • Pembrolizumab
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-17
Feb 17, 2022
I
Recruiting
  • Metastatic Melanoma
  • Unresectable Melanoma
  • Orange City, Florida
  • +1 more
2022-03-11
Mar 11, 2022
A
Not yet recruiting
  • Melanoma
  • (no location specified)
2022-03-23
Mar 23, 2022
A
Not yet recruiting
  • Non Hodgkin Lymphoma
  • Pembrolizumab
  • (no location specified)
2022-03-31
Mar 31, 2022
T
Not yet recruiting
  • Colorectal Cancer
  • Pembrolizumab
  • (no location specified)
2021-11-22
Nov 22, 2021
N
Active, not recruiting
  • Stage IIIA Non-Small Cell Lung Cancer
  • Cleveland, Ohio
    Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
2021-07-06
Jul 6, 2021
I
Not yet recruiting
  • Esophagogastric Adenocarcinoma
  • Pembrolizumab
  • +3 more
  • Heidelberg, Germany
    Universitätsklinikum Heidelberg
2022-02-24
Feb 24, 2022
S
Completed
  • Hepatocellular Carcinoma
  • Pembrolizumab
  • Seoul, Korea, Republic of
    Samsung Medical Center
2022-01-25
Jan 25, 2022
A
Completed
  • Malignant Melanoma
  • pembrolizumab
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
2022-03-23
Mar 23, 2022
J
Recruiting
  • Pancreatic Cancer
  • Lexington, Kentucky
    University of Kentucky Markey Cancer Center
2022-02-26
Feb 26, 2022
I
Recruiting
  • Lymphoma, Extranodal NK-T-Cell
  • Pembrolizumab
  • Involved Field Radiation Therapy
  • Shanghai, China
    Shanghai Rui-Jin Hospital
2022-03-29
Mar 29, 2022
M
Not yet recruiting
  • Newly Diagnosed Glioblastoma
  • Pembrolizumab
  • (no location specified)
2022-02-22
Feb 22, 2022
M
Active, not recruiting
  • Nasopharyngeal Neoplasms
  • Pembrolizumab
  • +3 more
  • (no location specified)
2022-03-11
Mar 11, 2022
B
Not yet recruiting
  • Breast Cancer
  • HER2-positive Breast Cancer
  • Parkville, Victoria, Australia
    Peter MacCallum Cancer Centre
2022-03-06
Mar 6, 2022
U
Active, not recruiting
  • Solid Tumor
  • Stereotactic body radiotherapy (SBRT)
  • Pembrolizumab
  • Chicago, Illinois
    University of Chicago
2022-03-14
Mar 14, 2022
C
Active, not recruiting
  • Acral Lentiginous Melanoma
  • pembrolizumab
  • Hong Kong, Hong Kong
    Department of Clinical Oncology, Prince of Wales Hospital
2022-02-15
Feb 15, 2022
U
Active, not recruiting
  • Newly Diagnosed Glioblastoma
  • Pembrolizumab
  • Bern, Switzerland
  • +2 more
2022-02-21
Feb 21, 2022
U
Not yet recruiting
  • Renal Cell Cancer
  • (no location specified)
2022-02-21
Feb 21, 2022
Y
Terminated
  • Melanoma
  • Pembrolizumab
  • +2 more
  • Pittsburgh, Pennsylvania
    UPMC Cancer Center Hillman Cancer Center
2021-12-10
Dec 10, 2021
D
Withdrawn
  • Glioblastoma
  • Boston, Massachusetts
  • +1 more
2021-12-13
Dec 13, 2021
M
Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
2021-09-07
Sep 7, 2021
C
Not yet recruiting
  • Pancreatic Cancer
  • (no location specified)
2021-10-21
Oct 21, 2021